ArticleJournal of medicinal chemistry2025
Sulfanylbenzamides with Unique Side Chains to Improve Metabolic Stability, Pharmacokinetics, and Anti-HIV Activity.
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecules that inhibit HIV by mechanisms other than inhibition of viral enzymes may be helpful in the treatment of infections where viral resistance has developed. Simple sulfanylbenzamides inactivate HIV by disrupting the coordination of zinc in the viral nucleocapsid protein, resulting in immature and noninfectious virus. HIV nucleocapsid protein (NCp7) is highly conserved across all viral strains, and there is a very high barrier for the virus to develop resistance to sulfanylbenzamide inactivators. These types of molecules act as topical microbicides to prevent HIV infections in animal models, but their systemic use has not been possible due to rapid metabolism in the blood. In this article, we describe a strategy to chemically modify the side chains of sulfanylbenzamides with unique groups to protect the molecules from metabolism while preserving antiviral activity and low toxicity. In vivo pharmacokinetics demonstrates the success of this approach, leading to a new route of systemic administration for this class of molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.